EUCTR2017-002809-34-DK进行中（未招募）1 期
Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP) - EPA-Pol-04
SLA Pharma UK Ltd0 个研究点目标入组 204 人开始时间: 2019年5月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Must give written informed consent.
- •2.Male or female subjects, 18 to 65 years of age.
- •3.Known diagnosis of FAP defined as those with a pathogenic APC mutation and have had a previous colectomy with ileo-rectal anastomosis.
- •4.Subjects must have a preserved rectum.
- •5.Classified stage 1-3 on InSiGHT Polyposis Staging System (IPSS).
- •6.Subjects must show a willingness to abstain from regular use of non-steroidal anti-inflammatory medication for the trial. A cardioprotective dose of aspirin (75mg-100mg) will be permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 204
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. In subjects with previous ileo-rectal anastomosis = 20 polyps > 5mm in the rectum.
- •2. Subjects with an ileo-anal pouch.
- •3. Subjects unwilling to have regular sigmoidoscopy examination.
- •4. Subjects who are due to undergo gastro-intestinal surgery related to FAP.
- •5. History of invasive carcinoma in the past 3 years.
- •6. History of pelvic radiation.
- •7. Known allergic reaction or intolerant to fish or fish oils.
- •8. Known allergic reaction to excipients of IMP and placebo.
- •9. Subjects who are pregnant or breast-feeding at screening.
- •10. Subjects taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis other than low dose (75mg-100mg) cardioprotective dose. Regular use of other NSAIDS is defined in this protocol as use greater than 14-day treatment period, and one treatment per six months for the duration of the study.
- •11. Subjects taking NSAIDs regularly in the 3 months prior to entry (other than low dose aspirin).
- •12. Subjects taking NSAID, 5-aminosalicylic acid (5-ASA or mesalamine).
- •13.Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are unwilling to stop them for the duration of the study. Subjects previously taking fish oil must have a washout period of 2 months prior to study enrolment.
- •14.Subjects who are taking warfarin or other anticoagulants.
- •15.Experimental agents must have been discontinued at least 8 weeks prior to screening for a period equivalent to 5 half-lives of the agent (whichever is longer).
- •16.Subjects suffering from known disorders of clotting and blood coagulation.
- •17.Subjects who have significant abnormalities on their screening blood tests.
- •18.Subjects with gastrointestinal malabsorptive disease.
- •19.Subjects with uncontrolled hypercholesterolaemia.
- •20.Subjects who are deemed mentally incompetent or have a history of anorexia nervosa or bulimia.
- •21.Subjects who will be unavailable for the duration of the trial, deemed unable to comply with the requirements of the study protocol, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.
- •22.Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile, must use effective contraception (either combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects’ usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP.
- •23.Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels that have been confirmed to be in the postmenopausal range”. Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bil
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of a herbal combination product, Eviprostat N, in the treatment of moderate LUTS associated with benign prostatic hyperplasia” - EVE 2004/01Patients with moderate LUTS (Lower Urinary Tract Symptoms) associated with benign prostatic hyperplasiaMedDRA version: 7.0Level: LLTClassification code 10004446EUCTR2004-002901-57-DEPharmazeutische Fabrik Evers & Co. GmbH326
已完成
不适用
Randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and shedding of live-attenuated RSV vaccine in healthy adults<br>NL-OMON47495Intravacc48
进行中（未招募）
1 期
Clinical trial to compare APD421 (amisulpride) against a placebo for the treatment of patients feeling sick or being sick after an operation, who have previously been given preventative anti-sickness medicine.Post-operative nausea and vomitingMedDRA version: 19.0Level: PTClassification code 10066962Term: Procedural nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2015-003992-30-DEAcacia Pharma Ltd700
已完成
1 期
Safety and tolerability of increasing doses of ZY-19489 compared to placebo in healthy volunteers.MalariaACTRN12619000127101Cadila Healthcare Limited48
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled study of topicalGW842470X formulation in adult patients with moderate atopicdermatitisAtopic DermatitisEUCTR2005-005430-12-DEGlaxoSmithKline Research & Development Limited190